EA202092410A1 - Конъюгаты камптотецина с пептидом - Google Patents

Конъюгаты камптотецина с пептидом

Info

Publication number
EA202092410A1
EA202092410A1 EA202092410A EA202092410A EA202092410A1 EA 202092410 A1 EA202092410 A1 EA 202092410A1 EA 202092410 A EA202092410 A EA 202092410A EA 202092410 A EA202092410 A EA 202092410A EA 202092410 A1 EA202092410 A1 EA 202092410A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugates
camptothetcin
peptide
camptothecin
present
Prior art date
Application number
EA202092410A
Other languages
English (en)
Russian (ru)
Inventor
Скотт Джеффри
Райан Лиски
Морин РАЙАН
Джулия Кочран
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Publication of EA202092410A1 publication Critical patent/EA202092410A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
EA202092410A 2018-04-06 2019-04-05 Конъюгаты камптотецина с пептидом EA202092410A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862653961P 2018-04-06 2018-04-06
PCT/US2019/025968 WO2019195665A1 (en) 2018-04-06 2019-04-05 Camptothecin peptide conjugates

Publications (1)

Publication Number Publication Date
EA202092410A1 true EA202092410A1 (ru) 2021-02-09

Family

ID=68101237

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092410A EA202092410A1 (ru) 2018-04-06 2019-04-05 Конъюгаты камптотецина с пептидом

Country Status (16)

Country Link
US (3) US20190343828A1 (https=)
EP (1) EP3773736A4 (https=)
JP (2) JP7430643B2 (https=)
KR (1) KR20210006362A (https=)
CN (1) CN111936169A (https=)
AR (1) AR114473A1 (https=)
AU (1) AU2019247434A1 (https=)
BR (1) BR112020020466A2 (https=)
CA (1) CA3094313A1 (https=)
EA (1) EA202092410A1 (https=)
IL (2) IL310391A (https=)
MA (1) MA52669A (https=)
MX (1) MX2020010458A (https=)
SG (1) SG11202009527PA (https=)
TW (1) TW202010498A (https=)
WO (1) WO2019195665A1 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250114431A (ko) 2016-11-08 2025-07-29 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
CN112533951A (zh) 2018-05-09 2021-03-19 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN110590796B (zh) * 2018-06-12 2022-07-15 青岛海洋生物医药研究院股份有限公司 喜树碱衍生物及其制备方法和应用
JP7561141B2 (ja) * 2019-04-26 2024-10-03 イミュノジェン・インコーポレーテッド カンプトテシン誘導体
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
WO2021067393A1 (en) * 2019-10-01 2021-04-08 Memorial Sloan Kettering Cancer Center SMALL MOLECULE INHIBITORS OF Id PROTEINS
WO2021067820A1 (en) * 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
AU2020356955A1 (en) * 2019-10-04 2022-04-14 Seagen Inc. Camptothecin peptide conjugates
AU2020358859A1 (en) * 2019-10-04 2022-05-12 Seagen Inc. Anti-PD-L1 antibodies and antibody-drug conjugates
CN115052632B (zh) * 2020-01-15 2025-01-14 北京海步医药科技有限公司 靶向多肽-药物缀合物及其用途
CN113274507B (zh) * 2020-02-20 2025-02-28 亚飞（上海）生物医药科技有限公司 靶向递送和激活的免疫刺激性偶联复合物的制备和用途
MX2022010457A (es) 2020-02-25 2022-11-16 Mediboston Ltd Derivados de camptotecina y conjugados de esta.
CA3183602A1 (en) * 2020-05-13 2021-11-18 Seagen Inc. Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
CN116472064A (zh) * 2020-10-12 2023-07-21 昆山新蕴达生物科技有限公司 抗体-药物偶联物及其应用
WO2022093800A2 (en) 2020-10-27 2022-05-05 Elucida Oncology, Inc. Carrier particle-drug conjugates, self-immolative linkers, and uses thereof
AU2022207454A1 (en) * 2021-01-15 2023-06-22 R.P. Scherer Technologies, Llc Camptothecine antibody-drug conjugates and methods of use thereof
KR20250120438A (ko) * 2021-02-05 2025-08-08 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 캄프토테신 화합물, 그의 제조방법 및 그의 응용
MX2023008895A (es) * 2021-02-09 2023-08-09 Medilink Therapeutics Suzhou Co Ltd Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo.
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
TW202300148A (zh) * 2021-03-17 2023-01-01 大陸商江蘇恒瑞醫藥股份有限公司 喜樹鹼衍生物的製備方法
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
TW202547842A (zh) * 2021-04-29 2025-12-16 愛爾蘭商艾伯維製造管理無限公司 抗c-Met抗體藥物結合物
EP4349371A4 (en) * 2021-06-02 2025-06-25 Bio-Thera Solutions, Ltd. DRUG CONJUGATE AND USE THEREOF
CN113527418B (zh) * 2021-07-16 2022-05-03 成都普康唯新生物科技有限公司 一种ADC linker的制备方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
CA3228345A1 (en) * 2021-08-19 2023-02-23 Zhen Li Camptothecin derivative, and pharmaceutical composition and use thereof
AU2022350588A1 (en) 2021-09-27 2024-05-02 Evopoint Biosciences Co., Ltd. Antibody, antibody-drug conjugate thereof and use thereof
TW202339803A (zh) * 2021-11-09 2023-10-16 德商圖布里斯有限公司 包含磷(v)及喜樹鹼分子部分的共軛物
CN116199740A (zh) * 2021-12-01 2023-06-02 上海生物制品研究所有限责任公司 抗体药物偶联物及其用途
CN116354976B (zh) * 2021-12-27 2025-01-24 上海复旦张江生物医药股份有限公司 喜树碱衍生物的纯化方法
MX2024009174A (es) 2022-01-25 2024-08-09 Medilink Therapeutics Suzhou Co Ltd Anticuerpo contra her3, conjugado y uso del mismo.
CN118434741A (zh) * 2022-01-26 2024-08-02 苏州宜联生物医药有限公司 一种药物连接体偶联物的制备方法
AU2023225240A1 (en) 2022-02-24 2024-09-05 Evopoint Biosciences Co., Ltd. Antibody, and drug conjugate and use thereof
IL315508A (en) 2022-03-17 2024-11-01 Seagen Inc Camptothecin conjugates
IL315393A (en) 2022-03-25 2024-11-01 Zymeworks Bc Inc Antibody preparations for drugs targeting alpha acid receptor and methods of use
CN119173276A (zh) * 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
AR129066A1 (es) * 2022-04-14 2024-07-10 Debiopharm Res & Manufacturing S A Conjugados de ligando-fármaco con propiedades farmacocinéticas y de liberación de fármaco mejoradas
KR20230149752A (ko) * 2022-04-20 2023-10-27 주식회사 피노바이오 Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭
CA3250941A1 (en) 2022-04-29 2025-03-20 Systimmune, Inc. Conjugated ligand-drug containing a hydrophilic sugar structure
CN119546346A (zh) * 2022-05-04 2025-02-28 匹诺生物股份有限公司 与ddx5蛋白结合的喜树碱类药物与酸敏感性接头连接的缀合物及使用该缀合物的免疫缀合物
US20230357763A1 (en) * 2022-05-06 2023-11-09 James E. Summerton Morpholinos with Increased Delivery Efficiency
WO2023217227A1 (zh) 2022-05-12 2023-11-16 先声再明医药有限公司 喜树碱类衍生物及配体-药物偶联物
CN117143177A (zh) * 2022-05-30 2023-12-01 苏州宜联生物医药有限公司 一种药物连接体偶联物的制备方法及其中间体
CN118955615B (zh) * 2022-07-05 2026-01-30 上海药明合联生物技术有限公司 偶联连接子
JP2025524728A (ja) * 2022-07-15 2025-07-30 フィアン セラピューティクス エルティーディー 抗体－薬物複合体
WO2024054089A1 (ko) * 2022-09-08 2024-03-14 주식회사 피노바이오 신규 캄토테신 유도체 및 이를 포함하는 운반체-약물 접합체
CN117752813A (zh) 2022-09-26 2024-03-26 成都百利多特生物药业有限责任公司 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
WO2024073610A2 (en) * 2022-09-28 2024-04-04 Solve Therapeutics, Inc. Compositions and uses thereof
KR20250084919A (ko) 2022-10-14 2025-06-11 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 인간 ptk7에 결합하는 항체-약물 접합체 및 그의 제조 및 사용 방법
KR20250089514A (ko) * 2022-10-18 2025-06-18 자임워크스 비씨 인코포레이티드 글리피칸-3을 표적화하는 항체-약물 접합체 및 사용 방법
WO2024114318A1 (zh) 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 药物连接子化合物及其制备方法和用途
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
CN116712561A (zh) 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 含n-亚甲基酰胺连接子的抗体-药物偶联物
JP2026508145A (ja) * 2023-02-09 2026-03-10 ビーワン メディシンズ ワン ゲーエムベーハー 自己安定化リンカーコンジュゲート
CN118666946A (zh) * 2023-03-15 2024-09-20 上海亲合力生物医药科技股份有限公司 连接子及使用其的偶联药物、抗体偶联药物及其应用
WO2024210687A1 (ko) * 2023-04-06 2024-10-10 주식회사 피노바이오 항암 내성 극복을 위한 신규 캄토테신 유도체 및 이를 포함하는 항체-약물 접합체
WO2024227440A1 (zh) * 2023-05-04 2024-11-07 四川科伦博泰生物医药股份有限公司 稠环化合物及其制备方法和应用
EP4719381A1 (en) * 2023-06-05 2026-04-08 Tripartite Therapeutics Inc. Ligand-polar drug conjugates
WO2025040012A1 (zh) * 2023-08-18 2025-02-27 康诺亚生物医药科技（成都）有限公司 五环类活性化合物及其偶联物和用途
KR20250033119A (ko) * 2023-08-31 2025-03-07 주식회사 피노바이오 신규 캄토테신 유도체 및 이를 포함하는 항체-약물 접합체
WO2025051241A1 (zh) * 2023-09-06 2025-03-13 劲方医药科技(上海)股份有限公司 大环化合物及其抗体-药物偶联物
WO2025078841A2 (en) 2023-10-11 2025-04-17 Antikor Biopharma Limited Antibodies, conjugates, and uses thereof
CN120053678A (zh) * 2023-11-30 2025-05-30 上海医药集团股份有限公司 一种高喜树碱类抗体偶联药物、其制备方法及应用
WO2025124555A1 (en) * 2023-12-14 2025-06-19 Shanghai Micurx Pharmaceutical Co., Ltd. Ligand-drug conjugate of camptothecin analogs and use thereof
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
TW202602929A (zh) 2024-03-21 2026-01-16 美商思進公司 Ｃｄ２５抗體、抗體-藥物共軛體及彼等之用途
WO2025221986A1 (en) * 2024-04-18 2025-10-23 Cedars-Sinai Medical Center Targeted camptothecin derivatives for cancer treatment
WO2025223507A1 (zh) * 2024-04-25 2025-10-30 江苏康宁杰瑞生物制药有限公司 化合物及其偶联物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
JPH06228141A (ja) * 1992-01-24 1994-08-16 Takeda Chem Ind Ltd 縮合複素環誘導体、その塩、その製造法および用途
US5496830A (en) * 1994-09-14 1996-03-05 Johns Hopkins University Inhibition of hemoflagellates by camptothecin compounds
TW464652B (en) * 1996-10-30 2001-11-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
HK1047236A1 (zh) * 1999-05-14 2003-02-14 Imclone Llc 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
US6629995B1 (en) * 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
US6825206B1 (en) * 2000-11-16 2004-11-30 Research Triangle Institute Camptothecin compounds with a thioether group
US8877901B2 (en) * 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
CN101969970B (zh) * 2007-10-12 2014-10-15 西雅图基因公司 用抗体-药物偶联物联合治疗
DK2907824T3 (en) * 2012-10-11 2018-07-23 Daiichi Sankyo Co Ltd ANTIBODY-drug conjugate
JP6701077B2 (ja) * 2013-12-19 2020-05-27 シアトル ジェネティックス， インコーポレイテッド 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
JP7244987B2 (ja) * 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
TWI851577B (zh) * 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
AU2020356955A1 (en) * 2019-10-04 2022-04-14 Seagen Inc. Camptothecin peptide conjugates
AU2020358859A1 (en) * 2019-10-04 2022-05-12 Seagen Inc. Anti-PD-L1 antibodies and antibody-drug conjugates
CA3183602A1 (en) * 2020-05-13 2021-11-18 Seagen Inc. Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
MX2023006484A (es) * 2020-12-03 2023-06-20 Seagen Inc Modulacion de la respuesta inmunitaria mediante conjugados anticuerpo-farmaco anti-cd30.
JP2025501978A (ja) * 2022-01-05 2025-01-24 アジェンシス，インコーポレイテッド １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）で筋層浸潤性尿路上皮癌または筋層浸潤性膀胱癌を治療するための方法
IL315508A (en) * 2022-03-17 2024-11-01 Seagen Inc Camptothecin conjugates

Also Published As

Publication number Publication date
EP3773736A4 (en) 2022-01-05
JP7430643B2 (ja) 2024-02-13
IL277748B2 (en) 2024-07-01
CA3094313A1 (en) 2019-10-10
JP2024042054A (ja) 2024-03-27
IL277748B1 (en) 2024-03-01
IL310391A (en) 2024-03-01
BR112020020466A2 (pt) 2021-01-12
JP2021521111A (ja) 2021-08-26
US20190343828A1 (en) 2019-11-14
KR20210006362A (ko) 2021-01-18
CN111936169A (zh) 2020-11-13
SG11202009527PA (en) 2020-10-29
AU2019247434A1 (en) 2020-10-08
MX2020010458A (es) 2021-01-29
AR114473A1 (es) 2020-09-09
MA52669A (fr) 2021-02-17
US20250135018A1 (en) 2025-05-01
US20220193069A1 (en) 2022-06-23
WO2019195665A1 (en) 2019-10-10
TW202010498A (zh) 2020-03-16
EP3773736A1 (en) 2021-02-17
IL277748A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
EA202092410A1 (ru) Конъюгаты камптотецина с пептидом
MX2022003930A (es) Conjugados de péptido de camptotecina.
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
MX2022002682A (es) Anticuerpos anti-cd73.
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX385853B (es) Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr.
EA201991729A1 (ru) Антитела к tgf-бета и их применение
NZ706377A (en) Il-6 antagonists and uses thereof
EA201490677A1 (ru) Связывающие антиген cd27l белки
UA123202C2 (uk) Антитіло до тау-білка і його застосування
MY192248A (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
EA201892063A1 (ru) МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
PH12022550318A1 (en) Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
EA202191666A1 (ru) Антитела к il-27 и их применение
JOP20200295A1 (ar) أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها